STRATEC Biomedical AG
STRATEC Biomedical AG designs and manufactures automation and instrumentation solutions in the fields of in-vitro diagnostics and life sciences in Germany and internationally. The company operates through three segments: Instrumentation, Diatron, and Consumables. The Instrumentation segment designs and manufactures automated analyzer systems for clinical diagnostics and biotechnology customers. T… Read more
STRATEC Biomedical AG (SRBZF) - Total Liabilities
Latest total liabilities as of September 2024: $223.08 Million USD
Based on the latest financial reports, STRATEC Biomedical AG (SRBZF) has total liabilities worth $223.08 Million USD as of September 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
STRATEC Biomedical AG - Total Liabilities Trend (2014–2023)
This chart illustrates how STRATEC Biomedical AG's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
STRATEC Biomedical AG Competitors by Total Liabilities
The table below lists competitors of STRATEC Biomedical AG ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
FORTINET
BE:FO8
|
Germany | €7.94 Billion |
|
AfroCentric Investment Corp
JSE:ACT
|
South Africa | ZAC2.12 Billion |
|
CTS EVENTIM - Dusseldorf Stock Exchang
DU:EVD
|
Germany | €2.58 Billion |
|
CRTMF
OTCQB:CRTMF
|
USA | $4.59 Million |
|
Reach Energy Bhd
KLSE:5256
|
Malaysia | RM803.32 Million |
Liability Composition Analysis (2014–2023)
This chart breaks down STRATEC Biomedical AG's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.52 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.98 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.49 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how STRATEC Biomedical AG's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for STRATEC Biomedical AG (2014–2023)
The table below shows the annual total liabilities of STRATEC Biomedical AG from 2014 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | $233.25 Million | +35.36% |
| 2022-12-31 | $172.32 Million | +5.87% |
| 2021-12-31 | $162.77 Million | +2.14% |
| 2020-12-31 | $159.36 Million | +50.43% |
| 2017-12-31 | $105.94 Million | -8.38% |
| 2016-12-31 | $115.63 Million | +303.45% |
| 2015-12-31 | $28.66 Million | +11.53% |
| 2014-12-31 | $25.70 Million | -- |